IL1B and cryopyrin-associated periodic syndrome: IL‐1 inhibitory agents, anakinra (a modified IL‐1RA that binds and antagonized the IL‐1 receptor), canakinumab (an IL‐1 neutralizing antibody) and rilonacept (ligand‐binding domains of the extracellular portions of IL‐1 receptor component) are the main therapeutic approach for CAPS.